Skip to main content
Top
Published in: Endocrine 2/2017

01-02-2017 | Review

Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management

Authors: Ana M Ramos-Leví, Mónica Marazuela

Published in: Endocrine | Issue 2/2017

Login to get access

Abstract

Comorbidities related to the cardiovascular system are one of the most prevalent in patients with acromegaly, and contribute to an increased risk of morbidity and all-cause mortality. Specifically, hypertension, cardiomyopathy, heart valve disease, arrhythmias, atherosclerosis, coronary artery disease, and cardiac dysfunction may be frequent findings. Although the underlying physiopathology for each comorbidity may not be fully elucidated, uncontrolled growth hormone/insulin-like growth factor 1 excess, age, prolonged disease duration, and coexistence of other cardio-vascular risk factors are significant influencing variables. A simple diagnostic approach to screen for the presence of these comorbidities may allow prompt treatment and arrest the progression of cardiac abnormalities. In this article, we revise the most prevalent cardiovascular comorbidities and their pathophysiology in acromegalic patients, and we address some recommendations for their prompt diagnosis, management and treatment. Strengths and pitfalls of different diagnostic techniques that are currently being used and how different treatments can affect these complications will be further discussed.
Literature
1.
go back to reference I.M. Holdaway, R.C. Rajasoorya, G.D. Gamble, Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89, 667–674 (2004)PubMedCrossRef I.M. Holdaway, R.C. Rajasoorya, G.D. Gamble, Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89, 667–674 (2004)PubMedCrossRef
3.
go back to reference A. Giustina, P. Chanson, D. Kleinberg, M.D. Bronstein, D.R. Clemmons, A. Klibanski, A.J. van der Lely, C.J. Strasburger, S.W. Lamberts, K.K. Ho, F.F. Casanueva, S. Melmed; Acromegaly Consensus Group, Expert consensus document: a consensus on the medical treatment of acromegaly. Nat. Rev. Endocrinol. 10, 243–248 (2014)PubMedCrossRef A. Giustina, P. Chanson, D. Kleinberg, M.D. Bronstein, D.R. Clemmons, A. Klibanski, A.J. van der Lely, C.J. Strasburger, S.W. Lamberts, K.K. Ho, F.F. Casanueva, S. Melmed; Acromegaly Consensus Group, Expert consensus document: a consensus on the medical treatment of acromegaly. Nat. Rev. Endocrinol. 10, 243–248 (2014)PubMedCrossRef
4.
go back to reference R. López-Velasco, H.F. Escobar-Morreale, B. Vega, E. Villa, J.M. Sancho, J.L. Moya-Mur, R. García-Robles, Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? J. Clin. Endocrinol. Metab. 82, 1047–1053 (1997)PubMed R. López-Velasco, H.F. Escobar-Morreale, B. Vega, E. Villa, J.M. Sancho, J.L. Moya-Mur, R. García-Robles, Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? J. Clin. Endocrinol. Metab. 82, 1047–1053 (1997)PubMed
5.
go back to reference C. Sardella, D. Cappellani, C. Urbani, L. Manetti, G. Marconcini, L. Tomisti, I. Lupi, G. Rossi, I. Scattina, M. Lombardi, Di Bello V, C. Marcocci, E. Martino, F. Bogazzi, Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly. Eur. J. Endocrinol. 175, 443–453 (2016)PubMedCrossRef C. Sardella, D. Cappellani, C. Urbani, L. Manetti, G. Marconcini, L. Tomisti, I. Lupi, G. Rossi, I. Scattina, M. Lombardi, Di Bello V, C. Marcocci, E. Martino, F. Bogazzi, Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly. Eur. J. Endocrinol. 175, 443–453 (2016)PubMedCrossRef
6.
go back to reference G. Lombardi, A. Colao, P. Marzullo, D. Ferone, S. Longobardi, Esposito V, B. Merola, Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly. J. Endocrinol. 155(Suppl 1), S33–S37 (1997). discussion S39PubMed G. Lombardi, A. Colao, P. Marzullo, D. Ferone, S. Longobardi, Esposito V, B. Merola, Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly. J. Endocrinol. 155(Suppl 1), S33–S37 (1997). discussion S39PubMed
7.
go back to reference O.M. Dekkers, N.R. Biermasz, A.M. Pereira, J.A. Romijn, J.P. Vandenbroucke, Mortality in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab. 93, 61–67 (2008)PubMedCrossRef O.M. Dekkers, N.R. Biermasz, A.M. Pereira, J.A. Romijn, J.P. Vandenbroucke, Mortality in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab. 93, 61–67 (2008)PubMedCrossRef
8.
go back to reference L. Katznelson, E.R. Laws Jr, S. Melmed, M.E. Molitch, M.H. Murad, A. Utz, J.A. Wass, Endocrine Society: acromegaly: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 3933–3951 (2014)PubMedCrossRef L. Katznelson, E.R. Laws Jr, S. Melmed, M.E. Molitch, M.H. Murad, A. Utz, J.A. Wass, Endocrine Society: acromegaly: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 3933–3951 (2014)PubMedCrossRef
9.
go back to reference E. Ritvonen, E. Löyttyniemi, P. Jaatinen, T. Ebeling, L. Moilanen, P. Nuutila, R. Kauppinen-Mäkelin, C. Schalin-Jäntti, Mortality in acromegaly: a 20-year follow-up study. Endocr. Relat. Cancer 23, 469–480 (2015)PubMedCrossRef E. Ritvonen, E. Löyttyniemi, P. Jaatinen, T. Ebeling, L. Moilanen, P. Nuutila, R. Kauppinen-Mäkelin, C. Schalin-Jäntti, Mortality in acromegaly: a 20-year follow-up study. Endocr. Relat. Cancer 23, 469–480 (2015)PubMedCrossRef
10.
go back to reference A. Ramos-Levi, M. Marazuela, Sleep apnea syndrome in acromegalic patients: can morphological evaluation guide us to optimize treatment? Endocrine. 51, 203–204 (2016)PubMedCrossRef A. Ramos-Levi, M. Marazuela, Sleep apnea syndrome in acromegalic patients: can morphological evaluation guide us to optimize treatment? Endocrine. 51, 203–204 (2016)PubMedCrossRef
11.
go back to reference A. Colao, D. Ferone, P. Marzullo, G. Lombardi, Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 25, 102–152 (2004)PubMedCrossRef A. Colao, D. Ferone, P. Marzullo, G. Lombardi, Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 25, 102–152 (2004)PubMedCrossRef
12.
go back to reference M.S.1 Broder, M.P. Neary, E. Chang, D. Cherepanov, L. Katznelson, Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. Pituitary 17, 333–341 (2014)PubMedCrossRef M.S.1 Broder, M.P. Neary, E. Chang, D. Cherepanov, L. Katznelson, Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. Pituitary 17, 333–341 (2014)PubMedCrossRef
13.
go back to reference M. Bondanelli, M.R. Ambrosio, E.C. degli Uberti, Pathogenesis and prevalence of hypertension in acromegaly. Pituitary. 4, 239–249 (2001)PubMedCrossRef M. Bondanelli, M.R. Ambrosio, E.C. degli Uberti, Pathogenesis and prevalence of hypertension in acromegaly. Pituitary. 4, 239–249 (2001)PubMedCrossRef
14.
go back to reference F. Costenaro, A. Martin, R.F. Horn, M.A. Czepielewski, T.C. Rodrigues, Role of ambulatory blood pressure monitoring in patients with acromegaly. J. Hypertens. 34, 1357–1363 (2016)PubMedCrossRef F. Costenaro, A. Martin, R.F. Horn, M.A. Czepielewski, T.C. Rodrigues, Role of ambulatory blood pressure monitoring in patients with acromegaly. J. Hypertens. 34, 1357–1363 (2016)PubMedCrossRef
15.
go back to reference G. Vitale, R. Pivonello, R.S. Auriemma, E. Guerra, F. Milone, S. Savastano, G. Lombardi, A. Colao, Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin. Endocrinol. 63, 470–476 (2005)CrossRef G. Vitale, R. Pivonello, R.S. Auriemma, E. Guerra, F. Milone, S. Savastano, G. Lombardi, A. Colao, Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin. Endocrinol. 63, 470–476 (2005)CrossRef
16.
go back to reference A.S. Powlson, M. Gurnell, Cardiovascular disease and sleep-disordered breathing in acromegaly. Neuroendocrinology 103, 75–85 (2016)PubMedCrossRef A.S. Powlson, M. Gurnell, Cardiovascular disease and sleep-disordered breathing in acromegaly. Neuroendocrinology 103, 75–85 (2016)PubMedCrossRef
17.
go back to reference G. Brevetti, P. Marzullo, A. Silvestro, R. Pivonello, G. Oliva, C. di Somma, G. Lombardi, A. Colao, Early vascular alterations in acromegaly. J. Clin. Endocrinol. Metab. 87, 3174–3179 (2002)PubMedCrossRef G. Brevetti, P. Marzullo, A. Silvestro, R. Pivonello, G. Oliva, C. di Somma, G. Lombardi, A. Colao, Early vascular alterations in acromegaly. J. Clin. Endocrinol. Metab. 87, 3174–3179 (2002)PubMedCrossRef
18.
go back to reference M. Terzolo, C. Matrella, A. Boccuzzi, S. Luceri, M. Borriero, G. Reimondo, A. Pia, E. Rovero, P. Paccotti, A. Angeli, Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features. J. Endocrinol. Invest. 22, 48–54 (1999)PubMedCrossRef M. Terzolo, C. Matrella, A. Boccuzzi, S. Luceri, M. Borriero, G. Reimondo, A. Pia, E. Rovero, P. Paccotti, A. Angeli, Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features. J. Endocrinol. Invest. 22, 48–54 (1999)PubMedCrossRef
19.
go back to reference C. Sardella, C. Urbani, M. Lombardi, A. Nuzzo, L. Manetti, I. Lupi, G. Rossi, S. Del Sarto, I. Scattina, V. Di Bello, E. Martino, F. Bogazzi, The beneficial effect of acromegaly control on blood pressure values in normotensive patients. Clin. Endocrinol. 81, 573–581 (2014)CrossRef C. Sardella, C. Urbani, M. Lombardi, A. Nuzzo, L. Manetti, I. Lupi, G. Rossi, S. Del Sarto, I. Scattina, V. Di Bello, E. Martino, F. Bogazzi, The beneficial effect of acromegaly control on blood pressure values in normotensive patients. Clin. Endocrinol. 81, 573–581 (2014)CrossRef
20.
go back to reference A.E. Schutte, M. Volpe, G. Tocci, E. Conti, Revisiting the relationship between blood pressure and insulin-like growth factor-1. Hypertension. 63, 1070–1077 (2014)PubMedCrossRef A.E. Schutte, M. Volpe, G. Tocci, E. Conti, Revisiting the relationship between blood pressure and insulin-like growth factor-1. Hypertension. 63, 1070–1077 (2014)PubMedCrossRef
21.
go back to reference P. Kamenicky, S. Viengchareun, A. Blanchard, G. Meduri, P. Zizzari, M. Imbert-Teboul, A. Doucet, P. Chanson, M. Lombès, Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly. Endocrinology 149, 3294–3305 (2008)PubMedPubMedCentralCrossRef P. Kamenicky, S. Viengchareun, A. Blanchard, G. Meduri, P. Zizzari, M. Imbert-Teboul, A. Doucet, P. Chanson, M. Lombès, Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly. Endocrinology 149, 3294–3305 (2008)PubMedPubMedCentralCrossRef
22.
go back to reference P. Kamenicky, A. Blanchard, M. Frank, S. Salenave, A. Letierce, M. Azizi, M. Lombès, P. Chanson, Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity. J. Clin. Endocrinol. Metab. 96, 2127–2135 (2011)PubMedCrossRef P. Kamenicky, A. Blanchard, M. Frank, S. Salenave, A. Letierce, M. Azizi, M. Lombès, P. Chanson, Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity. J. Clin. Endocrinol. Metab. 96, 2127–2135 (2011)PubMedCrossRef
23.
go back to reference D. Rizzoni, E. Porteri, A. Giustina, C. De Ciuceis, I. Sleiman, G.E. Boari, M. Castellano, M.L. Muiesan, S. Bonadonna, A. Burattin, B. Cerudelli, E. Agabiti-Rosei, Acromegalic patients show the presence of hypertrophic remodeling of subcutaneous small resistance arteries. Hypertension 43, 561–565 (2004)PubMedCrossRef D. Rizzoni, E. Porteri, A. Giustina, C. De Ciuceis, I. Sleiman, G.E. Boari, M. Castellano, M.L. Muiesan, S. Bonadonna, A. Burattin, B. Cerudelli, E. Agabiti-Rosei, Acromegalic patients show the presence of hypertrophic remodeling of subcutaneous small resistance arteries. Hypertension 43, 561–565 (2004)PubMedCrossRef
24.
go back to reference A.K. Annamalai, A. Webb, N. Kandasamy, M. Elkhawad, S. Moir, F. Khan, K. Maki-Petaja, E.L. Gayton, C.H. Strey, S. O’Toole, S. Ariyaratnam, D.J. Halsall, A.N. Chaudhry, L. Berman, D.J. Scoffings, N.M. Antoun, D.P. Dutka, I.B. Wilkinson, J.M. Shneerson, J.D. Pickard, H.L. Simpson, M. Gurnell, A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J. Clin. Endocrinol. Metab. 98, 1040–1050 (2013)PubMedCrossRef A.K. Annamalai, A. Webb, N. Kandasamy, M. Elkhawad, S. Moir, F. Khan, K. Maki-Petaja, E.L. Gayton, C.H. Strey, S. O’Toole, S. Ariyaratnam, D.J. Halsall, A.N. Chaudhry, L. Berman, D.J. Scoffings, N.M. Antoun, D.P. Dutka, I.B. Wilkinson, J.M. Shneerson, J.D. Pickard, H.L. Simpson, M. Gurnell, A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J. Clin. Endocrinol. Metab. 98, 1040–1050 (2013)PubMedCrossRef
25.
go back to reference T.K. Hansen, J. Møller, K. Thomsen, E. Frandsen, R. Dall, J.O. Jørgensen, J.S. Christiansen, Effects of growth hormone on renal tubular handling of sodium in healthy humans. Am. J. Physiol. Endocrinol. Metab. 281, 1326–1332 (2001) T.K. Hansen, J. Møller, K. Thomsen, E. Frandsen, R. Dall, J.O. Jørgensen, J.S. Christiansen, Effects of growth hormone on renal tubular handling of sodium in healthy humans. Am. J. Physiol. Endocrinol. Metab. 281, 1326–1332 (2001)
26.
go back to reference F. Bogazzi, M. Lombardi, E. Strata, G. Aquaro, V. Di Bello, C. Cosci, C. Sardella, E. Talini, E. Martino, High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in vivo study using magnetic resonance imaging. Clin. Endocrinol. 68, 361–368 (2008)CrossRef F. Bogazzi, M. Lombardi, E. Strata, G. Aquaro, V. Di Bello, C. Cosci, C. Sardella, E. Talini, E. Martino, High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in vivo study using magnetic resonance imaging. Clin. Endocrinol. 68, 361–368 (2008)CrossRef
27.
go back to reference A. Colao, R. Baldelli, P. Marzullo, E. Ferretti, D. Ferone, P. Gargiulo, M. Petretta, G. Tamburrano, G. Lombardi, A. Liuzzi, Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J. Clin. Endocrinol. Metab. 85, 193–199 (2000)PubMed A. Colao, R. Baldelli, P. Marzullo, E. Ferretti, D. Ferone, P. Gargiulo, M. Petretta, G. Tamburrano, G. Lombardi, A. Liuzzi, Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J. Clin. Endocrinol. Metab. 85, 193–199 (2000)PubMed
28.
go back to reference A. Colao, P. Marzullo, C. Di Somma, G. Lombardi, Growth hormone and heart. Clin. Endocrinol. (Oxf). 54, 137–154 (2001)PubMedCrossRef A. Colao, P. Marzullo, C. Di Somma, G. Lombardi, Growth hormone and heart. Clin. Endocrinol. (Oxf). 54, 137–154 (2001)PubMedCrossRef
29.
go back to reference N.S. Freestone, S. Ribaric, W.T. Mason, The effect of insulin-like growth factor-1 on adult rat cardiac contractility. Mol. Cell. Biochem. 163–164, 223–229 (1996)PubMedCrossRef N.S. Freestone, S. Ribaric, W.T. Mason, The effect of insulin-like growth factor-1 on adult rat cardiac contractility. Mol. Cell. Biochem. 163–164, 223–229 (1996)PubMedCrossRef
30.
go back to reference H. Gouya, O. Vignaux, P. Le Roux, P. Chanson, J. Bertherat, X. Bertagna, P. Legmann, Rapidly reversible myocardial edema in patients with acromegaly: assessment with ultrafast T2 mapping in a single-breath-hold MRI sequence. Am. J. Roentgenol. 190, 1576–1582 (2008)CrossRef H. Gouya, O. Vignaux, P. Le Roux, P. Chanson, J. Bertherat, X. Bertagna, P. Legmann, Rapidly reversible myocardial edema in patients with acromegaly: assessment with ultrafast T2 mapping in a single-breath-hold MRI sequence. Am. J. Roentgenol. 190, 1576–1582 (2008)CrossRef
31.
go back to reference L. Saccà, R. Napoli, A. Cittadini, Growth hormone, acromegaly, and heart failure: an intricate triangulation. Clin. Endocrinol. 59, 660–671 (2003)CrossRef L. Saccà, R. Napoli, A. Cittadini, Growth hormone, acromegaly, and heart failure: an intricate triangulation. Clin. Endocrinol. 59, 660–671 (2003)CrossRef
32.
go back to reference H. Bihan, C. Espinosa, H. Valdes-Socin, S. Salenave, J. Young, S. Levasseur, P. Assayag, A. Beckers, P. Chanson, Long-term outcome of patients with acromegaly and congestive heart failure. J. Clin. Endocrinol. Metab. 89, 5308–5313 (2004)PubMedCrossRef H. Bihan, C. Espinosa, H. Valdes-Socin, S. Salenave, J. Young, S. Levasseur, P. Assayag, A. Beckers, P. Chanson, Long-term outcome of patients with acromegaly and congestive heart failure. J. Clin. Endocrinol. Metab. 89, 5308–5313 (2004)PubMedCrossRef
33.
go back to reference M. Losa, K. von Werder, The heart in acromegaly. Growth Hormone and the Heart. A. Giustina (ed.) Kluwer Academic, Boston, 2001, 33–43CrossRef M. Losa, K. von Werder, The heart in acromegaly. Growth Hormone and the Heart. A. Giustina (ed.) Kluwer Academic, Boston, 2001, 33–43CrossRef
34.
go back to reference J. Isgaard, M. Arcopinto, K. Karason, A. Cittadini, GH and the cardiovascular system: an update on a topic at heart. Endocrine 48, 25–35 (2015)PubMedCrossRef J. Isgaard, M. Arcopinto, K. Karason, A. Cittadini, GH and the cardiovascular system: an update on a topic at heart. Endocrine 48, 25–35 (2015)PubMedCrossRef
35.
go back to reference A. Abreu, A.P. Tovar, R. Castellanos, A. Valenzuela, C.M. Giraldo, A.C. Pinedo, D.P. Guerrero, C.A. Barrera, H.I. Franco, A. Ribeiro-Oliveira Jr, L. Vilar, R.S.12 Jallad, F.G. Duarte, M. Gadelha, C.L. Boguszewski, J. Abucham, L.A. Naves, N.R. Musolino, M.E. de Faria, C. Rossato, M.D. Bronstein, Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary. 19, 448–457 (2016)PubMedPubMedCentralCrossRef A. Abreu, A.P. Tovar, R. Castellanos, A. Valenzuela, C.M. Giraldo, A.C. Pinedo, D.P. Guerrero, C.A. Barrera, H.I. Franco, A. Ribeiro-Oliveira Jr, L. Vilar, R.S.12 Jallad, F.G. Duarte, M. Gadelha, C.L. Boguszewski, J. Abucham, L.A. Naves, N.R. Musolino, M.E. de Faria, C. Rossato, M.D. Bronstein, Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary. 19, 448–457 (2016)PubMedPubMedCentralCrossRef
36.
go back to reference A.M. Pereira, S.W. van Thiel, J.R. Lindner, F. Roelfsema, E.E. van der Wall, H. Morreau, J.W. Smit, J.A. Romijn, J.J. Bax, Increased prevalence of regurgitant valvular heart disease in acromegaly. J. Clin. Endocrinol. Metab. 89, 71–75 (2004)PubMedCrossRef A.M. Pereira, S.W. van Thiel, J.R. Lindner, F. Roelfsema, E.E. van der Wall, H. Morreau, J.W. Smit, J.A. Romijn, J.J. Bax, Increased prevalence of regurgitant valvular heart disease in acromegaly. J. Clin. Endocrinol. Metab. 89, 71–75 (2004)PubMedCrossRef
37.
go back to reference A. Colao, L. Spinelli, P. Marzullo, R. Pivonello, M. Petretta, C. Di Somma, G. Vitale, D. Bonaduce, G. Lombardi, High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J. Clin. Endocrinol. Metab. 88, 3196–3201 (2003)PubMedCrossRef A. Colao, L. Spinelli, P. Marzullo, R. Pivonello, M. Petretta, C. Di Somma, G. Vitale, D. Bonaduce, G. Lombardi, High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J. Clin. Endocrinol. Metab. 88, 3196–3201 (2003)PubMedCrossRef
38.
go back to reference A.A. van der Klaauw, J.J. Bax, F. Roelfsema, G.B. Bleeker, E.R. Holman, E.P. Corssmit, E.E. van der Wall, J.W. Smit, J.A. Romijn, A.M. Pereira, Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm. IGF. Res. 16, 101–107 (2006)PubMedCrossRef A.A. van der Klaauw, J.J. Bax, F. Roelfsema, G.B. Bleeker, E.R. Holman, E.P. Corssmit, E.E. van der Wall, J.W. Smit, J.A. Romijn, A.M. Pereira, Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm. IGF. Res. 16, 101–107 (2006)PubMedCrossRef
39.
go back to reference A.A. van der Klaauw, J.J. Bax, J.W. Smit, E.R. Holman, V. Delgado, G.B. Bleeker, N.R. Biermasz, F. Roelfsema, J.A. Romijn, A.M. Pereira, Increased aortic root diameters in patients with acromegaly. Eur. J. Endocrinol. 159, 97–103 (2008)PubMedCrossRef A.A. van der Klaauw, J.J. Bax, J.W. Smit, E.R. Holman, V. Delgado, G.B. Bleeker, N.R. Biermasz, F. Roelfsema, J.A. Romijn, A.M. Pereira, Increased aortic root diameters in patients with acromegaly. Eur. J. Endocrinol. 159, 97–103 (2008)PubMedCrossRef
40.
go back to reference G. Kahaly, K.V. Olshausen, S. Mohr-Kahaly, R. Erbel, S. Boor, J. Beyer, J. Meyer, Arrhythmia profile in acromegaly. Eur. Heart J. 13, 51–56 (1992)PubMed G. Kahaly, K.V. Olshausen, S. Mohr-Kahaly, R. Erbel, S. Boor, J. Beyer, J. Meyer, Arrhythmia profile in acromegaly. Eur. Heart J. 13, 51–56 (1992)PubMed
41.
go back to reference S. Mosca, S. Paolillo, A. Colao, E. Bossone, A. Cittadini, F.L. Iudice, A. Parente, S. Conte, G. Rengo, D. Leosco, B. Trimarco, P.P. Filardi, Cardiovascular involvement in patients affected by acromegaly: an appraisal. Int. J. Cardiol. 167, 1712–1718 (2013)PubMedCrossRef S. Mosca, S. Paolillo, A. Colao, E. Bossone, A. Cittadini, F.L. Iudice, A. Parente, S. Conte, G. Rengo, D. Leosco, B. Trimarco, P.P. Filardi, Cardiovascular involvement in patients affected by acromegaly: an appraisal. Int. J. Cardiol. 167, 1712–1718 (2013)PubMedCrossRef
42.
go back to reference P. Maffei, C. Martini, A. Milanesi, A. Corfini, R. Mioni, E. de Carlo, C. Menegazzo, M. Scanarini, R. Vettor, G. Federspil, N. Sicolo, Late potentials and ventricular arrhythmias in acromegaly. Int. J. Cardiol. 104, 197–203 (2005)PubMedCrossRef P. Maffei, C. Martini, A. Milanesi, A. Corfini, R. Mioni, E. de Carlo, C. Menegazzo, M. Scanarini, R. Vettor, G. Federspil, N. Sicolo, Late potentials and ventricular arrhythmias in acromegaly. Int. J. Cardiol. 104, 197–203 (2005)PubMedCrossRef
43.
go back to reference A. Kırış, C. Erem, O.E. Turan, N. Civan, G. Kırış, I. Nuhoğlu, A. Ilter, H.O. Ersöz, M. Kutlu, Left ventricular synchronicity is impaired in patients with active acromegaly. Endocrine 44, 200–206 (2013)PubMedCrossRef A. Kırış, C. Erem, O.E. Turan, N. Civan, G. Kırış, I. Nuhoğlu, A. Ilter, H.O. Ersöz, M. Kutlu, Left ventricular synchronicity is impaired in patients with active acromegaly. Endocrine 44, 200–206 (2013)PubMedCrossRef
44.
go back to reference L. Warszawski, L. Kasuki, R. Sá, C.M. Dos Santos Silva, I. Volschan, I. Gottlieb, R.C. Pedrosa, M.R. Gadelha, Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-naïve acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment. Pituitary 19, 582–589 (2016)PubMedCrossRef L. Warszawski, L. Kasuki, R. Sá, C.M. Dos Santos Silva, I. Volschan, I. Gottlieb, R.C. Pedrosa, M.R. Gadelha, Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-naïve acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment. Pituitary 19, 582–589 (2016)PubMedCrossRef
45.
go back to reference A. Colao, S. Spiezia, G. Cerbone, R. Pivonello, P. Marzullo, D. Ferone, C. Di Somma, A.P. Assanti, G. Lombardi, Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin. Endocrinol. 54, 515–524 (2001)CrossRef A. Colao, S. Spiezia, G. Cerbone, R. Pivonello, P. Marzullo, D. Ferone, C. Di Somma, A.P. Assanti, G. Lombardi, Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin. Endocrinol. 54, 515–524 (2001)CrossRef
46.
go back to reference I. Kartal, H. Oflaz, B. Pamukçu, M. Meriç, F. Aral, N. Ozbey, F. Alagöl, Investigation of early atherosclerotic changes in acromegalic patients. Int. J. Clin. Pract. 64, 39–44 (2010)PubMedCrossRef I. Kartal, H. Oflaz, B. Pamukçu, M. Meriç, F. Aral, N. Ozbey, F. Alagöl, Investigation of early atherosclerotic changes in acromegalic patients. Int. J. Clin. Pract. 64, 39–44 (2010)PubMedCrossRef
47.
go back to reference A.N. Paisley, M. Banerjee, M. Rezai, R.E. Schofield, S. Balakrishnannair, A. Herbert, J.A. Lawrance, P.J. Trainer, J.K. Cruickshank, Changes in arterial stiffness but not carotid intimal thickness in acromegaly. J. Clin. Endocrinol. Metab. 96, 1486–1492 (2011)PubMedCrossRef A.N. Paisley, M. Banerjee, M. Rezai, R.E. Schofield, S. Balakrishnannair, A. Herbert, J.A. Lawrance, P.J. Trainer, J.K. Cruickshank, Changes in arterial stiffness but not carotid intimal thickness in acromegaly. J. Clin. Endocrinol. Metab. 96, 1486–1492 (2011)PubMedCrossRef
48.
go back to reference M. Bex, R. Abs, G. T’Sjoen, J. Mockel, B. Velkeniers, K. Muermans, D. Maiter, AcroBel--the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjects. Eur. J. Endocrinol. 157, 399–409 (2007)PubMedCrossRef M. Bex, R. Abs, G. T’Sjoen, J. Mockel, B. Velkeniers, K. Muermans, D. Maiter, AcroBel--the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjects. Eur. J. Endocrinol. 157, 399–409 (2007)PubMedCrossRef
49.
go back to reference M. Mercado, B. Gonzalez, G. Vargas, C. Ramirez, A.L. de los Monteros, E. Sosa, P. Jervis, P. Roldan, V. Mendoza, B. López-Félix, G. Guinto, Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J. Clin. Endocrinol. Metab. 99, 4438–4446 (2014)PubMedCrossRef M. Mercado, B. Gonzalez, G. Vargas, C. Ramirez, A.L. de los Monteros, E. Sosa, P. Jervis, P. Roldan, V. Mendoza, B. López-Félix, G. Guinto, Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J. Clin. Endocrinol. Metab. 99, 4438–4446 (2014)PubMedCrossRef
50.
go back to reference O. Dupuy, T. Petrossian, L. Bordier, H. Mayaudon, B. Bauduceau, Registre de L’Acromégalie. Hypertension and acromegaly in the elderly: French registry data. Arch. Mal. Coeur. Vaiss. 100, 660–663 (2007)PubMed O. Dupuy, T. Petrossian, L. Bordier, H. Mayaudon, B. Bauduceau, Registre de L’Acromégalie. Hypertension and acromegaly in the elderly: French registry data. Arch. Mal. Coeur. Vaiss. 100, 660–663 (2007)PubMed
51.
go back to reference S. Cannavo, B. Almoto, G. Cavalli, S. Squadrito, G. Romanello, M.T. Vigo, F. Fiumara, S. Benvenga, F. Trimarchi, Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J. Clin. Endocrinol. Metab. 91, 3766–3772 (2006)PubMedCrossRef S. Cannavo, B. Almoto, G. Cavalli, S. Squadrito, G. Romanello, M.T. Vigo, F. Fiumara, S. Benvenga, F. Trimarchi, Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J. Clin. Endocrinol. Metab. 91, 3766–3772 (2006)PubMedCrossRef
52.
go back to reference F. Bogazzi, L. Battolla, C. Spinelli, G. Rossi, S. Gavioli, V. Di Bello, C. Cosci, C. Sardella, D. Volterrani, E. Talini, P. Pepe, F. Falaschi, G. Mariani, E.50H. Martino, J. Akutsu, G. Kreutzer, D. Wasmeier, C. Ropers, M. Rost, Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J. Clin. Endocrinol. Metab. 92, 4271–4277 (2007)PubMedCrossRef F. Bogazzi, L. Battolla, C. Spinelli, G. Rossi, S. Gavioli, V. Di Bello, C. Cosci, C. Sardella, D. Volterrani, E. Talini, P. Pepe, F. Falaschi, G. Mariani, E.50H. Martino, J. Akutsu, G. Kreutzer, D. Wasmeier, C. Ropers, M. Rost, Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J. Clin. Endocrinol. Metab. 92, 4271–4277 (2007)PubMedCrossRef
53.
go back to reference H. Akutsu, J. Kreutzer, G. Wasmeier, D. Ropers, C. Rost, M. Möhlig, H. Wallaschofski, M. Buchfelder, C. Schöfl, Acromegaly per se does not increase the risk for coronary artery disease. Eur. J. Endocrinol. 162, 879–886 (2010)PubMedCrossRef H. Akutsu, J. Kreutzer, G. Wasmeier, D. Ropers, C. Rost, M. Möhlig, H. Wallaschofski, M. Buchfelder, C. Schöfl, Acromegaly per se does not increase the risk for coronary artery disease. Eur. J. Endocrinol. 162, 879–886 (2010)PubMedCrossRef
54.
go back to reference A. Giustina, F.F. Casanueva, F. Cavagnini, P. Chanson, D. Clemmons, L.A. Frohman, R. Gaillard, K. Ho, P. Jaquet, D.L. Kleinberg, S.W. Lamberts, G. Lombardi, M. Sheppard, C.J. Strasburger, M.L. Vance, J.A. Wass, S. Melmed, Diagnosis and treatment of acromegaly complications. J. Endocrinol. Invest. 26, 1242–1247 (2003)PubMedCrossRef A. Giustina, F.F. Casanueva, F. Cavagnini, P. Chanson, D. Clemmons, L.A. Frohman, R. Gaillard, K. Ho, P. Jaquet, D.L. Kleinberg, S.W. Lamberts, G. Lombardi, M. Sheppard, C.J. Strasburger, M.L. Vance, J.A. Wass, S. Melmed, Diagnosis and treatment of acromegaly complications. J. Endocrinol. Invest. 26, 1242–1247 (2003)PubMedCrossRef
55.
go back to reference S. Melmed, F.F. Casanueva, A. Klibanski, M.D. Bronstein, P. Chanson, S.W. Lamberts, C.J. Strasburger, J.A. Wass, A. Giustina, A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16, 294–302 (2013)PubMedCrossRef S. Melmed, F.F. Casanueva, A. Klibanski, M.D. Bronstein, P. Chanson, S.W. Lamberts, C.J. Strasburger, J.A. Wass, A. Giustina, A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16, 294–302 (2013)PubMedCrossRef
56.
go back to reference G. Minniti, M.L. Jaffrain-Rea, C. Moroni, R. Baldelli, E. Ferretti, R. Cassone, A. Gulino, G. Tamburrano, Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics. Clin. Endocrinol. 49, 101–106 (1998)CrossRef G. Minniti, M.L. Jaffrain-Rea, C. Moroni, R. Baldelli, E. Ferretti, R. Cassone, A. Gulino, G. Tamburrano, Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics. Clin. Endocrinol. 49, 101–106 (1998)CrossRef
57.
go back to reference A. Colao, L. Spinelli, A. Cuocolo, S. Spiezia, D. Bonaduce, M. Salvatore, G. Lombardi, Cardiovascular consequences of early-onset growth hormone excess. J. Clin. Endoccrinol. Metab. 87, 3097–3104 (2002)CrossRef A. Colao, L. Spinelli, A. Cuocolo, S. Spiezia, D. Bonaduce, M. Salvatore, G. Lombardi, Cardiovascular consequences of early-onset growth hormone excess. J. Clin. Endoccrinol. Metab. 87, 3097–3104 (2002)CrossRef
58.
go back to reference M. Galderisi, G. Vitale, A. Bianco, R. Pivonello, G. Lombardi, Divitiis Od, Colao A, Pulsed tissue Doppler identifies subclinical myocardial biventricular dysfunction in active acromegaly. Clin. Endocrinol. 64, 390–397 (2006) M. Galderisi, G. Vitale, A. Bianco, R. Pivonello, G. Lombardi, Divitiis Od, Colao A, Pulsed tissue Doppler identifies subclinical myocardial biventricular dysfunction in active acromegaly. Clin. Endocrinol. 64, 390–397 (2006)
59.
go back to reference L. Spinelli, M. Petretta, G. Verderame, G. Carbone, A.A. Venetucci, A. Petretta, W. Acampa, D. Bonaduce, A. Colao, A. Cuocolo, Left ventricular diastolic function and cardiac performance during exercise in patients with acromegaly. J. Clin. Endocrinol. Metab. 88, 4105–1409 (2003)PubMedCrossRef L. Spinelli, M. Petretta, G. Verderame, G. Carbone, A.A. Venetucci, A. Petretta, W. Acampa, D. Bonaduce, A. Colao, A. Cuocolo, Left ventricular diastolic function and cardiac performance during exercise in patients with acromegaly. J. Clin. Endocrinol. Metab. 88, 4105–1409 (2003)PubMedCrossRef
60.
go back to reference C.M. dos Santos Silva, I. Gottlieb, I. Volschan, L. Kasuki, L. Warszawski, G.A. Balarini Lima, S.S. Xavier, R.C. Pedrosa, L.V. Neto, M.R. Gadelha, Low Frequency of Cardiomyopathy Using Cardiac Magnetic Resonance Imaging in an Acromegaly Contemporary Cohort. J. Clin. Endocrinol. Metab. 100, 4447–4455 (2015)PubMedCrossRef C.M. dos Santos Silva, I. Gottlieb, I. Volschan, L. Kasuki, L. Warszawski, G.A. Balarini Lima, S.S. Xavier, R.C. Pedrosa, L.V. Neto, M.R. Gadelha, Low Frequency of Cardiomyopathy Using Cardiac Magnetic Resonance Imaging in an Acromegaly Contemporary Cohort. J. Clin. Endocrinol. Metab. 100, 4447–4455 (2015)PubMedCrossRef
61.
go back to reference J.M. Dekker, E.G. Schouten, P. Klootwijk, J. Pool, D. Kromhout, Association between QT interval and coronary heart disease in middle-aged and elderly men. The Zutphen Study. Circulation 90, 779–785 (1994)PubMedCrossRef J.M. Dekker, E.G. Schouten, P. Klootwijk, J. Pool, D. Kromhout, Association between QT interval and coronary heart disease in middle-aged and elderly men. The Zutphen Study. Circulation 90, 779–785 (1994)PubMedCrossRef
62.
go back to reference M. Unubol, U. Eryilmaz, E. Guney, M. Ture, C. Akgullu, QT dispersion in patients with acromegaly. Endocrine 43, 419–423 (2013)PubMedCrossRef M. Unubol, U. Eryilmaz, E. Guney, M. Ture, C. Akgullu, QT dispersion in patients with acromegaly. Endocrine 43, 419–423 (2013)PubMedCrossRef
63.
go back to reference H. Baser, N. Akar Bayram, B. Polat, B. Evranos, R. Ersoy, E. Bozkurt, B. Cakir, The evaluation of QT intervals during diagnosis and after follow-up in acromegaly patients. Acta Med. Port. 27, 428–432 (2014)PubMedCrossRef H. Baser, N. Akar Bayram, B. Polat, B. Evranos, R. Ersoy, E. Bozkurt, B. Cakir, The evaluation of QT intervals during diagnosis and after follow-up in acromegaly patients. Acta Med. Port. 27, 428–432 (2014)PubMedCrossRef
64.
go back to reference M. Dural, G. Kabakci, N. Cinar, T. Erbaş, U. Canpolat, K.M. Gürses, L. Tokgözoğlu, A. Oto, E.B. Kaya, H. Yorgun, L. Sahiner, S. Dağdelen, K. Aytemir, Assessment of cardiac autonomic functions by heart rate recovery, heart rate variability and QT dynamicity parameters in patients with acromegaly. Pituitary 17, 163–170 (2014)PubMedCrossRef M. Dural, G. Kabakci, N. Cinar, T. Erbaş, U. Canpolat, K.M. Gürses, L. Tokgözoğlu, A. Oto, E.B. Kaya, H. Yorgun, L. Sahiner, S. Dağdelen, K. Aytemir, Assessment of cardiac autonomic functions by heart rate recovery, heart rate variability and QT dynamicity parameters in patients with acromegaly. Pituitary 17, 163–170 (2014)PubMedCrossRef
65.
go back to reference A. Colao, The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin. Endocrinol. 69, 347–358 (2008)CrossRef A. Colao, The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin. Endocrinol. 69, 347–358 (2008)CrossRef
66.
go back to reference M. Yaron, E. Izkhakov, J. Sack, I. Azzam, E. Osher, K. Tordjman, N. Stern, Y. Greenman, Arterial properties in acromegaly: relation to disease activity and associated cardiovascular risk factors. Pituitary 19, 322–331 (2016)PubMedCrossRef M. Yaron, E. Izkhakov, J. Sack, I. Azzam, E. Osher, K. Tordjman, N. Stern, Y. Greenman, Arterial properties in acromegaly: relation to disease activity and associated cardiovascular risk factors. Pituitary 19, 322–331 (2016)PubMedCrossRef
67.
go back to reference T.D. Bradley, J.S. Floras, Obstructive sleep apnoea and its cardiovascular consequences. Lancet. 373, 82–93 (2009)PubMedCrossRef T.D. Bradley, J.S. Floras, Obstructive sleep apnoea and its cardiovascular consequences. Lancet. 373, 82–93 (2009)PubMedCrossRef
68.
go back to reference M.1 Stelmachowska-Banaś, G. Zieliński, P. Zdunowski, J. Podgórski, W. Zgliczyński, The impact of transsphenoidal surgery on glucose homeostasis and insulin resistance in acromegaly. Neurol. Neurochir. Pol. 45, 328–334 (2011)PubMed M.1 Stelmachowska-Banaś, G. Zieliński, P. Zdunowski, J. Podgórski, W. Zgliczyński, The impact of transsphenoidal surgery on glucose homeostasis and insulin resistance in acromegaly. Neurol. Neurochir. Pol. 45, 328–334 (2011)PubMed
69.
go back to reference A.M. Ramos-Leví, I. Bernabeu, C. Álvarez-Escolá, J. Aller, T. Lucas, P. de Miguel, L. Rodríguez-Cañete, M.A. Sampedro-Núñez, I. Halperin, M. Puig-Domingo, M. Marazuela, Long-term treatment with pegvisomant for acromegaly: a 10-year experience. Clin. Endocrinol. 84, 540–550 (2016)CrossRef A.M. Ramos-Leví, I. Bernabeu, C. Álvarez-Escolá, J. Aller, T. Lucas, P. de Miguel, L. Rodríguez-Cañete, M.A. Sampedro-Núñez, I. Halperin, M. Puig-Domingo, M. Marazuela, Long-term treatment with pegvisomant for acromegaly: a 10-year experience. Clin. Endocrinol. 84, 540–550 (2016)CrossRef
70.
go back to reference L. Katznelson, J.L. Atkinson, D.M. Cook, S.Z. Ezzat, A.H. Hamrahian, K.K. Miller, American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly—2011. update. Endocr. Pract. 17(Suppl 4), 1–44 (2011)PubMedCrossRef L. Katznelson, J.L. Atkinson, D.M. Cook, S.Z. Ezzat, A.H. Hamrahian, K.K. Miller, American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly—2011. update. Endocr. Pract. 17(Suppl 4), 1–44 (2011)PubMedCrossRef
71.
go back to reference A. Colao, P. Marzullo, A. Cuocolo, L. Spinelli, R. Pivonello, D. Bonaduce, M. Salvatore, G. Lombardi, Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin. Endocrinol. 58, 169–176 (2003)CrossRef A. Colao, P. Marzullo, A. Cuocolo, L. Spinelli, R. Pivonello, D. Bonaduce, M. Salvatore, G. Lombardi, Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin. Endocrinol. 58, 169–176 (2003)CrossRef
72.
go back to reference A. Colao, Long-term acromegaly and associated cardiovascular complications: a case-based review. Best Pract. Res. Clin. Endocrinol. Metab. 23(Suppl 1), S31-8 (2009) A. Colao, Long-term acromegaly and associated cardiovascular complications: a case-based review. Best Pract. Res. Clin. Endocrinol. Metab. 23(Suppl 1), S31-8 (2009)
73.
go back to reference G. Minniti, C. Moroni, M.L. Jaffrain-Rea, V. Esposito, A. Santoro, C. Affricano, C. Cantore, G. Tamburrano, R. Cassone, Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin. Endocrinol. 55, 307–313 (2001)CrossRef G. Minniti, C. Moroni, M.L. Jaffrain-Rea, V. Esposito, A. Santoro, C. Affricano, C. Cantore, G. Tamburrano, R. Cassone, Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin. Endocrinol. 55, 307–313 (2001)CrossRef
74.
go back to reference A. Colao, A. Cuocolo, P. Marzullo, E. Nicolai, D. Ferone, A.M. Della Morte, R. Pivonello, M. Salvatore, G. Lombardi, Is the acromegalia cardiomyopathy reversible? Effect of 5 year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance. J. Clin. Endocrinol. Metab. 86, 1551–1557 (2001)PubMed A. Colao, A. Cuocolo, P. Marzullo, E. Nicolai, D. Ferone, A.M. Della Morte, R. Pivonello, M. Salvatore, G. Lombardi, Is the acromegalia cardiomyopathy reversible? Effect of 5 year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance. J. Clin. Endocrinol. Metab. 86, 1551–1557 (2001)PubMed
75.
go back to reference A. Colao, P. Marzullo, D. Ferone, L. Spinelli, A. Cuocolo, D. Bonaduce, M. Salvatore, V. Boerlin, I. Lancranjan, G. Lombardi, Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J. Clin. Endocrinol. Metab. 85, 3132–3140 (2000)PubMed A. Colao, P. Marzullo, D. Ferone, L. Spinelli, A. Cuocolo, D. Bonaduce, M. Salvatore, V. Boerlin, I. Lancranjan, G. Lombardi, Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J. Clin. Endocrinol. Metab. 85, 3132–3140 (2000)PubMed
76.
go back to reference P. Maison, A.I. Tropeano, I. Macquin-Mavier, A. Giustina, P. Chanson, Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab. 92, 1743–1747 (2007)PubMedCrossRef P. Maison, A.I. Tropeano, I. Macquin-Mavier, A. Giustina, P. Chanson, Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab. 92, 1743–1747 (2007)PubMedCrossRef
77.
go back to reference L. De Marinis, A. Bianchi, G. Mazziotti, M. Mettimano, D. Milardi, A. Fusco, V. Cimino, G. Maira, A. Pontecorvi, A. Giustina, The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. Pituitary 11, 13–20 (2008)PubMedCrossRef L. De Marinis, A. Bianchi, G. Mazziotti, M. Mettimano, D. Milardi, A. Fusco, V. Cimino, G. Maira, A. Pontecorvi, A. Giustina, The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. Pituitary 11, 13–20 (2008)PubMedCrossRef
78.
go back to reference A. Colao, Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary 15, 50–58 (2012)PubMedCrossRef A. Colao, Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary 15, 50–58 (2012)PubMedCrossRef
79.
go back to reference G. Lombardi, A. Colao, P. Marzullo, B. Biondi, E. Palmieri, S. Fazio, Multicenter Italian study group on Lanreotide: improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J. Endocrinol. Invest. 25, 971–976 (2002)PubMedCrossRef G. Lombardi, A. Colao, P. Marzullo, B. Biondi, E. Palmieri, S. Fazio, Multicenter Italian study group on Lanreotide: improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J. Endocrinol. Invest. 25, 971–976 (2002)PubMedCrossRef
80.
go back to reference L.M. Fatti, M. Scacchi, E. Lavezzi, F. Pecori Giraldi, M. De Martin, P. Toja, G. Michailidis, M. Stramba-Badiale, F. Cavagnini, Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clin. Endocrinol. 65, 626–630 (2006)CrossRef L.M. Fatti, M. Scacchi, E. Lavezzi, F. Pecori Giraldi, M. De Martin, P. Toja, G. Michailidis, M. Stramba-Badiale, F. Cavagnini, Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clin. Endocrinol. 65, 626–630 (2006)CrossRef
81.
go back to reference A. Colao, J. Marek, M.I. Goth, P. Caron, J.M. Kuhn, F.M. Minuto, N.J. Weissman, No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J. Clin. Endocrinol. Metab. 93, 2243–2248 (2008)PubMedCrossRef A. Colao, J. Marek, M.I. Goth, P. Caron, J.M. Kuhn, F.M. Minuto, N.J. Weissman, No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J. Clin. Endocrinol. Metab. 93, 2243–2248 (2008)PubMedCrossRef
82.
go back to reference C. Erem, H.O. Ersöz, K. Ukinç, A.M. Avunduk, A. Hacihasanoglu, M. Koçak, Acromegaly presenting with diabetic ketoacidosis, associated with retinitis pigmentosa and octreotide-induced bradycardia: a case report and a review of the literature. Endocrine 30, 145–149 (2006)PubMedCrossRef C. Erem, H.O. Ersöz, K. Ukinç, A.M. Avunduk, A. Hacihasanoglu, M. Koçak, Acromegaly presenting with diabetic ketoacidosis, associated with retinitis pigmentosa and octreotide-induced bradycardia: a case report and a review of the literature. Endocrine 30, 145–149 (2006)PubMedCrossRef
83.
go back to reference C.B.1 Vianna, M.L. Vieira, C. Mady, B. Liberman, A.E. Durazzo, M. Knoepfelmacher, L.R. Salgado, J.A. Ramires, Treatment of acromegaly improves myocardial abnormalities. Am. Heart J. 143, 873–876 (2002)PubMedCrossRef C.B.1 Vianna, M.L. Vieira, C. Mady, B. Liberman, A.E. Durazzo, M. Knoepfelmacher, L.R. Salgado, J.A. Ramires, Treatment of acromegaly improves myocardial abnormalities. Am. Heart J. 143, 873–876 (2002)PubMedCrossRef
84.
go back to reference W.H. Smith, R.U. Nair, D. Adamson, M.T. Kearney, S.G. Ball, A.J. Balmforth, Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts. J. Endocrinol. 187, 379–386 (2005)PubMedCrossRef W.H. Smith, R.U. Nair, D. Adamson, M.T. Kearney, S.G. Ball, A.J. Balmforth, Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts. J. Endocrinol. 187, 379–386 (2005)PubMedCrossRef
85.
go back to reference A. Colao, P. Cappabianca, P. Caron, E. De Menis, A.J. Farrall, M.R. Gadelha, A. Hmissi, A. Rees, M. Reincke, M. Safari, G. T’Sjoen, H. Bouterfa, R.C. Cuneo, Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin. Endocrinol. 70, 757–768 (2009)CrossRef A. Colao, P. Cappabianca, P. Caron, E. De Menis, A.J. Farrall, M.R. Gadelha, A. Hmissi, A. Rees, M. Reincke, M. Safari, G. T’Sjoen, H. Bouterfa, R.C. Cuneo, Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin. Endocrinol. 70, 757–768 (2009)CrossRef
86.
go back to reference A. Colao, R. Pivonello, M. Galderisi, P. Cappabianca, R.S. Auriemma, M. Galdiero, L.M. Cavallo, F. Esposito, G. Lombardi, Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J. Clin. Endocrinol. Metab. 93, 2639–2646 (2008)PubMedCrossRef A. Colao, R. Pivonello, M. Galderisi, P. Cappabianca, R.S. Auriemma, M. Galdiero, L.M. Cavallo, F. Esposito, G. Lombardi, Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J. Clin. Endocrinol. Metab. 93, 2639–2646 (2008)PubMedCrossRef
87.
go back to reference A. Colao, R.S. Auriemma, M. Galdiero, G. Lombardi, R. Pivonello, Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J. Clin. Endocrinol. Metab. 94, 3746–3756 (2009)PubMedCrossRef A. Colao, R.S. Auriemma, M. Galdiero, G. Lombardi, R. Pivonello, Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J. Clin. Endocrinol. Metab. 94, 3746–3756 (2009)PubMedCrossRef
88.
go back to reference G. Tolis, N.G. Angelopoulos, E. Katounda, G. Rombopoulos, V. Kaltzidou, D. Kaltsas, A. Protonotariou, A. Lytras, Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. J. Neuroendocrinol. 83, 249–257 (2006)CrossRef G. Tolis, N.G. Angelopoulos, E. Katounda, G. Rombopoulos, V. Kaltzidou, D. Kaltsas, A. Protonotariou, A. Lytras, Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. J. Neuroendocrinol. 83, 249–257 (2006)CrossRef
89.
go back to reference E. Couture, V. Bongard, J.C. Maiza, A. Bennet, P. Caron, Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide. Pituitary 15, 518–525 (2012)PubMedCrossRef E. Couture, V. Bongard, J.C. Maiza, A. Bennet, P. Caron, Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide. Pituitary 15, 518–525 (2012)PubMedCrossRef
90.
go back to reference R. Baldelli, C. Battista, F. Leonetti, M.R. Ghiggi, M.C. Ribaudo, A. Paoloni, E. D’Amico, E. Ferretti, R. Baratta, A. Liuzzi, V. Trischitta, G. Tamburrano, Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin. Endocrinol. 59, 492–429 (2003)CrossRef R. Baldelli, C. Battista, F. Leonetti, M.R. Ghiggi, M.C. Ribaudo, A. Paoloni, E. D’Amico, E. Ferretti, R. Baratta, A. Liuzzi, V. Trischitta, G. Tamburrano, Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin. Endocrinol. 59, 492–429 (2003)CrossRef
91.
go back to reference M.R. Gadelha, M.D. Bronstein, T. Brue, M. Coculescu, M. Fleseriu, M. Guitelman, V. Pronin, G. Raverot, I. Shimon, K.K. Lievre, J. Fleck, M. Aout, A.M. Pedroncelli, A. Colao, Pasireotide C2402 Study Group. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet. Diabetes Endocrinol. 2, 875–884 (2014)PubMedCrossRef M.R. Gadelha, M.D. Bronstein, T. Brue, M. Coculescu, M. Fleseriu, M. Guitelman, V. Pronin, G. Raverot, I. Shimon, K.K. Lievre, J. Fleck, M. Aout, A.M. Pedroncelli, A. Colao, Pasireotide C2402 Study Group. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet. Diabetes Endocrinol. 2, 875–884 (2014)PubMedCrossRef
92.
go back to reference A. Colao, M.D. Bronstein, P. Freda, F. Gu, C.C. Shen, M. Gadelha, M. Fleseriu, A.J. van der Lely, A.J. Farrall, K. Hermosillo Reséndiz, M. Ruffin, Y. Chen, M. Sheppard, Pasireotide C2305 Study Group. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J. Clin. Endocrinol. Metab. 99, 791–799 (2014)PubMedPubMedCentralCrossRef A. Colao, M.D. Bronstein, P. Freda, F. Gu, C.C. Shen, M. Gadelha, M. Fleseriu, A.J. van der Lely, A.J. Farrall, K. Hermosillo Reséndiz, M. Ruffin, Y. Chen, M. Sheppard, Pasireotide C2305 Study Group. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J. Clin. Endocrinol. Metab. 99, 791–799 (2014)PubMedPubMedCentralCrossRef
93.
go back to reference A. Colao, R. Pivonello, R.S. Auriemma, M.C. De Martino, M. Bidlingmaier, F. Briganti, F. Tortora, P. Burman, I.A. Kourides, C.J. Strasburger, G. Lombardi, Efficacy of 12-months of treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur. J. Endocrinol. 154, 467–477 (2006)PubMedCrossRef A. Colao, R. Pivonello, R.S. Auriemma, M.C. De Martino, M. Bidlingmaier, F. Briganti, F. Tortora, P. Burman, I.A. Kourides, C.J. Strasburger, G. Lombardi, Efficacy of 12-months of treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur. J. Endocrinol. 154, 467–477 (2006)PubMedCrossRef
94.
go back to reference C. Berg, S. Petersenn, H. Lahner, B.L. Herrmann, M. Buchfelder, M. Droste, G.K. Stalla, C.J. Strasburger, U. Roggenbuck, N. Lehmann, S. Moebus, K.H. Jöckel, S. Möhlenkamp, R. Erbel, B. Saller, K. Mann, Investigative Group of the Heinz Nixdorf Recall Study and the German Pegvisomant Observational Study Board and Investigators. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J. Clin. Endocrinol. Metab. 95, 3648–3656 (2010)PubMedCrossRef C. Berg, S. Petersenn, H. Lahner, B.L. Herrmann, M. Buchfelder, M. Droste, G.K. Stalla, C.J. Strasburger, U. Roggenbuck, N. Lehmann, S. Moebus, K.H. Jöckel, S. Möhlenkamp, R. Erbel, B. Saller, K. Mann, Investigative Group of the Heinz Nixdorf Recall Study and the German Pegvisomant Observational Study Board and Investigators. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J. Clin. Endocrinol. Metab. 95, 3648–3656 (2010)PubMedCrossRef
95.
go back to reference R. Pivonello, M. Galderisi, R.S. Auriemma, M.C. De Martino, M. Galdiero, A. Ciccarelli, A. D’Errico, I. Kourides, P. Burman, G. Lombardi, A. Colao, Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J. Clin. Endocrinol. Metab. 92, 476–482 (2007)PubMedCrossRef R. Pivonello, M. Galderisi, R.S. Auriemma, M.C. De Martino, M. Galdiero, A. Ciccarelli, A. D’Errico, I. Kourides, P. Burman, G. Lombardi, A. Colao, Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J. Clin. Endocrinol. Metab. 92, 476–482 (2007)PubMedCrossRef
96.
go back to reference M.C. De Martino, R.S. Auriemma, G. Brevetti, G. Vitale, V. Schiano, M. Galdiero, L. Grasso, G. Lombardi, A. Colao, R. Pivonello, The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. J. Endocrinol. Invest. 33, 663–670 (2010)PubMedCrossRef M.C. De Martino, R.S. Auriemma, G. Brevetti, G. Vitale, V. Schiano, M. Galdiero, L. Grasso, G. Lombardi, A. Colao, R. Pivonello, The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. J. Endocrinol. Invest. 33, 663–670 (2010)PubMedCrossRef
97.
go back to reference E. Kuhn, L. Maione, A. Bouchachi, M. Rozière, S. Salenave, S. Brailly-Tabard, J. Young, P. Kamenicky, P. Assayag, P. Chanson, Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. Eur. J. Endocrinol. 173, 693–702 (2015)PubMedPubMedCentralCrossRef E. Kuhn, L. Maione, A. Bouchachi, M. Rozière, S. Salenave, S. Brailly-Tabard, J. Young, P. Kamenicky, P. Assayag, P. Chanson, Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. Eur. J. Endocrinol. 173, 693–702 (2015)PubMedPubMedCentralCrossRef
98.
go back to reference R.S. Auriemma, R. Pivonello, M.C. De Martino, G. Cudemo, L.F. Grasso, M. Galdiero, Y. Perone, A. Colao, Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. Eur. J. Endocrinol. 168, 15–22 (2012)PubMedCrossRef R.S. Auriemma, R. Pivonello, M.C. De Martino, G. Cudemo, L.F. Grasso, M. Galdiero, Y. Perone, A. Colao, Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. Eur. J. Endocrinol. 168, 15–22 (2012)PubMedCrossRef
99.
go back to reference R.S. Auriemma, L.F. Grasso, M. Galdiero, M. Galderisi, C. Pivonello, C. Simeoli, M.C. De Martino, R. Ferrigno, M. Negri, C. de Angelis, R. Pivonello, A. Colao, Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine (2016 Jun 13). doi:10.1007/s12020-016-0995-5 R.S. Auriemma, L.F. Grasso, M. Galdiero, M. Galderisi, C. Pivonello, C. Simeoli, M.C. De Martino, R. Ferrigno, M. Negri, C. de Angelis, R. Pivonello, A. Colao, Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine (2016 Jun 13). doi:10.​1007/​s12020-016-0995-5
100.
go back to reference R. Luboshitzky, D. Barzilai, Bromocriptine for an acromegalic patient. Improvement in cardiac function and carpal tunnel syndrome. JAMA 244, 1825–1827 (1980)PubMedCrossRef R. Luboshitzky, D. Barzilai, Bromocriptine for an acromegalic patient. Improvement in cardiac function and carpal tunnel syndrome. JAMA 244, 1825–1827 (1980)PubMedCrossRef
101.
go back to reference L. Sandret, P. Maison, P. Chanson, Place of cabergoline in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 96, 1327–1335 (2011)PubMedCrossRef L. Sandret, P. Maison, P. Chanson, Place of cabergoline in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 96, 1327–1335 (2011)PubMedCrossRef
102.
go back to reference M. Marazuela, A. Ramos-Leví, M. Sampedro-Núñez, I. Bernabeu, Cabergoline treatment in acromegaly: pros. Endocrine 46, 215–219 (2014)PubMedCrossRef M. Marazuela, A. Ramos-Leví, M. Sampedro-Núñez, I. Bernabeu, Cabergoline treatment in acromegaly: pros. Endocrine 46, 215–219 (2014)PubMedCrossRef
103.
go back to reference L. Maione, C. Garcia, A. Bouchachi, N. Kallel, P. Maison, S. Salenave, J. Young, P. Assayag, P. Chanson, No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. J. Clin. Endocrinol. Metab. 97, E1714–E1719 (2012)PubMedCrossRef L. Maione, C. Garcia, A. Bouchachi, N. Kallel, P. Maison, S. Salenave, J. Young, P. Assayag, P. Chanson, No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. J. Clin. Endocrinol. Metab. 97, E1714–E1719 (2012)PubMedCrossRef
104.
go back to reference L. Kasuki, L. Vieira Neto, M.R. Gadelha, Cabergoline treatment in acromegaly: cons. Endocrine. 46, 220–225 (2014)PubMedCrossRef L. Kasuki, L. Vieira Neto, M.R. Gadelha, Cabergoline treatment in acromegaly: cons. Endocrine. 46, 220–225 (2014)PubMedCrossRef
105.
go back to reference A. Baldwin, T. Cundy, J. Butler, A.D. Timmis, Progression of cardiovascular disease in acromegalic patients treated by external pituitary irradiation. Acta. Endocrinol. 100, 581–587 (1985) A. Baldwin, T. Cundy, J. Butler, A.D. Timmis, Progression of cardiovascular disease in acromegalic patients treated by external pituitary irradiation. Acta. Endocrinol. 100, 581–587 (1985)
106.
go back to reference J. Ayuk, R.N. Clayton, G. Holder, M.C. Sheppard, P.M. Stewart, A.S. Bates, Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J. Clin. Endocrinol. Metab. 89, 1613–1617 (2004)PubMedCrossRef J. Ayuk, R.N. Clayton, G. Holder, M.C. Sheppard, P.M. Stewart, A.S. Bates, Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J. Clin. Endocrinol. Metab. 89, 1613–1617 (2004)PubMedCrossRef
107.
go back to reference G. Ntali, N. Karavitaki, Efficacy and complications of pituitary irradiation. Endocrinol. Metab. Clin. North. Am. 44, 117–126 (2015)PubMedCrossRef G. Ntali, N. Karavitaki, Efficacy and complications of pituitary irradiation. Endocrinol. Metab. Clin. North. Am. 44, 117–126 (2015)PubMedCrossRef
Metadata
Title
Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management
Authors
Ana M Ramos-Leví
Mónica Marazuela
Publication date
01-02-2017
Publisher
Springer US
Published in
Endocrine / Issue 2/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1191-3

Other articles of this Issue 2/2017

Endocrine 2/2017 Go to the issue